Profile data is unavailable for this security.
About the company
IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. The Company's lead program, INB-400, is in a Phase II clinical trial in which autologous, genetically modified gamma-delta T cells are assessed in glioblastoma (GBM). Its additional programs include Phase I trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for the treatment of patients with hematologic malignancies that are undergoing hematopoietic stem cell transplantation (HSCT). In addition, the Company’s DeltEx platform has yielded a portfolio of preclinical programs, including INB-300 and INB-500, focused on addressing acute myeloid leukemia (AML) and other solid and hematological tumor types.
- Revenue in USD (TTM)0.00
- Net income in USD-31.04m
- Incorporated2018
- Employees31.00
- LocationIN8BIO, Inc.Empire State Building350 5Th Avenue, Suite 5330NEW YORK 10118United StatesUSA
- Phone+1 (646) 600-6438
- Fax+1 (302) 655-5049
- Websitehttps://www.in8bio.com
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NKGen Biotech Inc | -100.00bn | -100.00bn | 32.60m | 63.00 | -- | -- | -- | -- | -- | -- | -- | -2.46 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -100.00 | -- | -210.06 | -- | -- | -- |
LianBio - ADR | 0.00 | -87.98m | 32.96m | 163.00 | -- | 0.1615 | -- | -- | -0.8195 | -0.8195 | 0.00 | 1.89 | 0.00 | -- | -- | 0.00 | -28.62 | -- | -35.22 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 43.82 | -- | -- | -- |
Aligos Therapeutics Inc | 13.79m | -99.59m | 33.00m | 67.00 | -- | 0.5565 | -- | 2.39 | -1.51 | -1.51 | 0.1796 | 0.7592 | 0.1105 | -- | -- | 208,969.70 | -79.78 | -51.20 | -98.27 | -59.73 | -- | -- | -722.06 | -1,399.21 | -- | -- | 0.0037 | -- | 11.66 | -- | 8.71 | -- | -62.36 | -- |
ImmuCell Corp | 21.28m | -3.90m | 33.43m | 74.00 | -- | 1.35 | -- | 1.57 | -0.5030 | -0.5030 | 2.75 | 3.18 | 0.494 | 2.29 | 9.03 | 269,401.50 | -9.05 | -5.16 | -9.97 | -5.53 | 27.55 | 40.04 | -18.31 | -12.64 | 1.00 | -8.14 | 0.3204 | -- | -5.90 | 9.72 | -131.56 | -- | -1.39 | -- |
Immuneering Corp | 0.00 | -54.18m | 33.51m | 65.00 | -- | 0.4257 | -- | -- | -1.86 | -1.86 | 0.00 | 2.65 | 0.00 | -- | -- | 0.00 | -55.37 | -- | -58.58 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -5.86 | -- | -- | -- |
Surrozen Inc | 0.00 | -37.58m | 35.15m | 42.00 | -- | 0.7684 | -- | -- | -18.44 | -18.44 | 0.00 | 14.30 | 0.00 | -- | -- | 0.00 | -67.75 | -- | -77.52 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -19.55 | -- | -- | -- |
IN8BIO, Inc. | 0.00 | -31.04m | 35.23m | 31.00 | -- | 1.97 | -- | -- | -0.9154 | -0.9154 | 0.00 | 0.4049 | 0.00 | -- | -- | 0.00 | -123.61 | -74.18 | -145.63 | -84.42 | -- | -- | -- | -- | -- | -- | 0.0556 | -- | -- | -- | -5.21 | -- | -4.54 | -- |
Mink Therapeutics Inc | 0.00 | -20.59m | 35.49m | 31.00 | -- | -- | -- | -- | -0.5964 | -0.5964 | 0.00 | -0.585 | 0.00 | -- | -- | 0.00 | -175.32 | -- | -3,661.37 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 19.77 | -- | -- | -- |
Carmell Corp | 0.00 | -18.29m | 36.22m | 9.00 | -- | -- | -- | -- | -1.58 | -1.49 | 0.00 | -0.0719 | 0.00 | -- | -- | 0.00 | -428.46 | -- | -- | -- | 58.60 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -75.70 | -- | -- | -- |
Curis Inc | 9.81m | -47.73m | 36.84m | 48.00 | -- | 3.89 | -- | 3.75 | -8.68 | -8.68 | 1.77 | 1.61 | 0.1253 | -- | 4.39 | 204,416.70 | -60.97 | -37.25 | -69.58 | -41.12 | 97.60 | 96.05 | -486.45 | -409.44 | -- | -- | 0.00 | -- | -1.37 | -0.7891 | 16.34 | -- | -- | -- |
Aeon Biopharma Inc | 0.00 | -485.01m | 37.58m | 10.00 | -- | -- | -- | -- | -13.04 | -13.04 | 0.00 | -5.20 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -27.67 | -- | -- | -- | -- | -631.85 | -- | -- | -- |
Angion Biomedica Corp | 0.00 | -38.99m | 37.79m | 32.00 | -- | 7.72 | -- | -- | -6.63 | -6.63 | 0.00 | 0.4765 | 0.00 | -- | -- | 0.00 | -117.72 | -105.91 | -133.85 | -331.69 | -- | -- | -- | -712.81 | -- | -- | 0.00 | -- | -100.00 | -- | 9.31 | -- | -- | -- |
Atara Biotherapeutics Inc | 34.70m | -233.11m | 37.81m | 173.00 | -- | -- | -- | 1.09 | -52.93 | -52.93 | 7.54 | -20.43 | 0.1485 | 0.9947 | 1.92 | 154,240.00 | -99.76 | -70.20 | -213.09 | -86.94 | 69.30 | -- | -671.70 | -1,559.33 | 0.50 | -- | -- | -- | -86.51 | -- | -20.95 | -- | -49.14 | -- |
Akari Therapeutics PLC (ADR) | -100.00bn | -100.00bn | 38.03m | 9.00 | -- | -- | -- | -- | -- | -- | -- | -0.4449 | -- | -- | -- | -- | -- | -149.95 | -- | -435.18 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 43.61 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Transcend Partners LLCas of 17 Apr 2024 | 3.22m | 7.30% |
AIGH Capital Management LLCas of 31 Mar 2024 | 2.87m | 6.52% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 1.42m | 3.23% |
Ensign Peak Advisors, Inc.as of 31 Mar 2024 | 1.12m | 2.53% |
683 Capital Management LLCas of 31 Mar 2024 | 614.75k | 1.39% |
Sigma Planning Corp.as of 31 Mar 2024 | 515.08k | 1.17% |
Alyeska Investment Group LPas of 31 Mar 2024 | 446.02k | 1.01% |
Voss Capital LLCas of 31 Mar 2024 | 323.48k | 0.73% |
Geode Capital Management LLCas of 31 Mar 2024 | 280.54k | 0.64% |
Stonegate Investment Group LLCas of 31 Mar 2024 | 180.00k | 0.41% |